Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.
GV
Gaorong Ventures
Activity from announced rounds
Activity in this selectionSeries B
Gaorong Ventures, also identified as Gaorong Capital, is the investment organization connected to Axoft and Moonwalk financing histories.
Recorded funding activity
Moonwalk develops medicines targeting fat-tissue pathways, while Axoft develops implanted brain-computer interfaces. The recorded activity also includes Anew’s combination of molecular models and experimental biology for drug discovery. These companies pursue different clinical technologies.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $70M 1 disclosed · full round size, not this investor’s share